Orange Book product · Generic (ANDA)
CARMUSTINE
CARMUSTINE
At a glance
Oct 20, 2023
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 20, 2023
2 yr 8 mo ago
Today
Pharmaceutical detail
Active ingredient
CARMUSTINE
Strength
100MG/VIAL
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 215730
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CARMUSTINE
- 2022CARMUSTINEBrand (NDA)
NDA 215000 · ACCORD HLTHCARE
- 1996GLIADELBrand (NDA)
NDA 020637 · AZURITY
- —BICNUBrand (NDA)
NDA 017422 · AVET LIFESCIENCES
- 2023CARMUSTINEGeneric (ANDA)
ANDA 214814 · MSN
- 2023CARMUSTINEGeneric (ANDA)
ANDA 215368 · PHARMOBEDIENT
- 2022CARMUSTINEGeneric (ANDA)
ANDA 214117 · ACCORD HLTHCARE
- 2022CARMUSTINEGeneric (ANDA)
ANDA 211011 · INGENUS PHARMS LLC
- 2021CARMUSTINEGeneric (ANDA)
ANDA 213460 · MEITHEAL
- 2021CARMUSTINEGeneric (ANDA)
ANDA 211202 · HENGRUI PHARMA
- 2020CARMUSTINEGeneric (ANDA)
ANDA 213207 · DR REDDYS
- 2019CARMUSTINEGeneric (ANDA)
ANDA 209278 · PENN LIFE
- 2018CARMUSTINEGeneric (ANDA)
ANDA 211229 · AMNEAL
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
